0001209191-20-028070.txt : 20200508
0001209191-20-028070.hdr.sgml : 20200508
20200508182538
ACCESSION NUMBER: 0001209191-20-028070
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200506
FILED AS OF DATE: 20200508
DATE AS OF CHANGE: 20200508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PATTERSON LEONE D
CENTRAL INDEX KEY: 0001233539
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 20862143
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 800 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc.
DATE OF NAME CHANGE: 20100921
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-06
0
0001501756
Adverum Biotechnologies, Inc.
ADVM
0001233539
PATTERSON LEONE D
C/O ADVERUM BIOTECHNOLOGIES, INC.
800 SAGINAW DRIVE
REDWOOD CITY
CA
94063
1
1
0
0
CEO, President and Director
Common Stock
2020-05-06
4
M
0
20000
3.44
A
143659
D
Common Stock
2020-05-06
4
S
0
20000
20.02
D
123659
D
Stock Option (Right to Buy)
3.44
2020-05-06
4
M
0
20000
0.00
D
2026-06-15
Common Stock
20000
155576
D
The balance of shares reflected in Reporting Person's prior Form 4 was inadvertently reflected as 123,429 shares and should have been reflected as 123,659 shares. The Form 4 originally reflecting the incorrect balance, filed with the SEC on 2/10/2020, has been amended to reflect the correct end of period balance in Column 5 of Table I in that filing.
This transaction was pursuant to a 10b5-1 Plan.
Represents weighted average sales price. The shares were sold at prices ranging from $20.00 to $20.09. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Twenty-Five Percent (25%) of the total shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48 of the total shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall be vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Leone Patterson, by /s/ Thomas Leung, Attorney-in-Fact
2020-05-08